131 related articles for article (PubMed ID: 16646003)
1. A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor alpha agents.
Lurati A; Pontikaki I; Teruzzi B; Desiati F; Gerloni V; Gattinara M; Cimaz R; Fantini F
Arthritis Rheum; 2006 May; 54(5):1602-7. PubMed ID: 16646003
[TBL] [Abstract][Full Text] [Related]
2. When should the use of biological agents be considered in persistent oligoarticular juvenile idiopathic arthritis patients?
Polat MC; Çelikel E; Tekin ZE; Kurt T; Kaplan MM; Güngörer V; Tekgöz N; Sezer M; Karagöl C; Coşkun S; Öner N; Sezer S; Acar BÇ
Eur J Pediatr; 2024 Jun; 183(6):2725-2731. PubMed ID: 38554171
[TBL] [Abstract][Full Text] [Related]
3. Origins of Discordant Responses among 3 Rheumatoid Arthritis Improvement Criteria.
Ward MM; Guthrie LC; Alba MI; Dasgupta A
J Rheumatol; 2018 Jun; 45(6):745-752. PubMed ID: 29606667
[TBL] [Abstract][Full Text] [Related]
4. Ten-year safety and clinical benefit from open-label etanercept treatment in children and young adults with juvenile idiopathic arthritis.
Vojinović J; Foeldvari I; Dehoorne J; Panaviene V; Susic G; Horneff G; Stanevicha V; Kobusinska K; Zuber Z; Dobrzyniecka B; Akikusa J; Avcin T; Borlenghi C; Arthur E; Tatulych SY; Zang C; Tsekouras V; Vlahos B; Martini A; Ruperto N
Rheumatology (Oxford); 2024 Jan; 63(1):140-148. PubMed ID: 37140539
[TBL] [Abstract][Full Text] [Related]
5. Role of Serum MRP8/14 in Predicting Response to Methotrexate in Children With Juvenile Idiopathic Arthritis.
Bagri NK; Karmakar S; Haldar P; Lodha R; Kabra SK
J Clin Rheumatol; 2021 Dec; 27(8):e336-e341. PubMed ID: 32658390
[TBL] [Abstract][Full Text] [Related]
6. Childhood-onset rheumatoid arthritis at a tertiary hospital in Senegal, West Africa.
Sabounji MM; Lissimo H; Deme A
Pediatr Rheumatol Online J; 2023 Sep; 21(1):98. PubMed ID: 37700346
[TBL] [Abstract][Full Text] [Related]
7. Economic impact of juvenile idiopathic arthritis and familial Mediterranean fever.
Yucel IK; Seyahi E; Kasapcopur O; Arisoy N
Rheumatol Int; 2012 Jul; 32(7):1955-62. PubMed ID: 21461856
[TBL] [Abstract][Full Text] [Related]
8. The relationship of the immune response mediator genes’ polymorphic variants with the methotrexate efficacy in juvenile idiopathic arthritis.
Nazarova L; Danilko K; Malievsky V; Karimov D; Bakirov A; Viktorova T
Turk J Med Sci; 2020 Jun; 50(4):1038-1047. PubMed ID: 31958219
[TBL] [Abstract][Full Text] [Related]
9. Defining criteria for rheumatoid arthritis patient-derived disease activity score that correspond to Disease Activity Score 28 and Clinical Disease Activity Index based disease states and response criteria.
Leung AM; Farewell D; Lau CS; Choy EH
Rheumatology (Oxford); 2016 Nov; 55(11):1954-1958. PubMed ID: 27477805
[TBL] [Abstract][Full Text] [Related]
10. Features and Clinical Course of Infantile Juvenile Idiopathic Arthritis.
Campbell JA; Shenoi S
J Clin Rheumatol; 2022 Mar; 28(2):e609-e611. PubMed ID: 33843769
[TBL] [Abstract][Full Text] [Related]
11. Predictors of European League Against Rheumatism (EULAR) good response, DAS-28 remission and sustained responses to TNF-inhibitors in rheumatoid arthritis: a prospective study in refractory disease.
Mohammed RH; Farahat F; Kewan HH; Bukhari MA
Springerplus; 2015; 4():207. PubMed ID: 25977895
[TBL] [Abstract][Full Text] [Related]
12. Secukinumab-Induced Crohn's Disease in a Patient Treated for Juvenile Idiopathic Arthritis.
Edupuganti S; Khine S; Gupta R; Yadav D; Singh A
Cureus; 2023 Aug; 15(8):e43825. PubMed ID: 37736437
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of biologic immunosuppressive treatment in juvenile idiopathic arthritis associated with inborn errors of immunity.
Accardo V; Pagnini I; Maccora I; Marrani E; Mastrolia MV; Simonini G
Front Pediatr; 2024; 12():1353825. PubMed ID: 38468871
[TBL] [Abstract][Full Text] [Related]
14. Clinical utility of etanercept in the treatment of arthritides in children and adolescents.
Dore RK
Adolesc Health Med Ther; 2014; 5():35-48. PubMed ID: 24729739
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Medication Withdrawal in Patients with Non-systemic Juvenile Idiopathic Arthritis in Japan Using a Web-based Survey.
Ebato T; Kishi T; Akamine K; Nozawa T; Imagawa T; Bando Y; Miyamae T
Mod Rheumatol; 2024 Mar; ():. PubMed ID: 38441307
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Methotrexate Intolerance in Children With Morphea.
McColl J; Laxer RM; Pope E; Sibbald C
J Pediatr Pharmacol Ther; 2023; 28(6):559-564. PubMed ID: 38130351
[TBL] [Abstract][Full Text] [Related]
17. Tumor-necrosis factor α-rich environment alters type-I interferon response to viral stimuli in patients with juvenile idiopathic arthritis by altering myeloid dendritic cell phenotype.
Zentsova I; Klocperk A; Bloomfield M; Kubesova H; Malcova H; Cebecauerova D; Horvath R; Sediva A; Parackova Z
Clin Immunol; 2024 May; 262():110170. PubMed ID: 38460895
[TBL] [Abstract][Full Text] [Related]
18. Current medical treatments for juvenile idiopathic arthritis.
Ruperto N; Martini A
Front Pharmacol; 2011; 2():60. PubMed ID: 22013422
[TBL] [Abstract][Full Text] [Related]
19. Developmental pharmacogenetics in pediatric rheumatology: utilizing a new paradigm to effectively treat patients with juvenile idiopathic arthritis with methotrexate.
Becker ML; Leeder JS
Hum Genomics Proteomics; 2010 Jun; 2010():257120. PubMed ID: 20981233
[TBL] [Abstract][Full Text] [Related]
20. Response to Jia and Wang.
Liu X; Liu Q; Yao X; Zhang M; Cui C; Li H; Liu D
Clin Infect Dis; 2021 Jul; 73(2):352-353. PubMed ID: 33170206
[No Abstract] [Full Text] [Related]
[Next] [New Search]
